- |||||||||| pegylated liposomal doxorubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Review, Journal: Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements. (Pubmed Central) - Jul 26, 2022
This review intends to highlight the recent advances in nanomedicine in BC treatment and diagnosis, emphasizing the targeting of BC cells that overexpress receptors of epidermal growth factors. Researchers may gain insight from these strategies to design and develop more tailored nanomedicine for BC to achieve further improvements in cancer specificity, antitumorigenic effects, anti-metastasis effects, and drug resistance reversal effects.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC) (7.2.F - Fécamp Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1359;
P3
Background Standard Cx for PSROC (> 6 months after last platinum dose) includes carboplatin plus pegylated liposomal doxorubicin (CbD) or gemcitabine (CbG) or paclitaxel (CbP) with or without bev...Pts were randomised 2:1 to Atz (1200 mg, d1, q3w or 800 mg, d1&15, q4w with CbD up to 24 months [m]) or placebo (Pbo) with Cx at investigator-choice (CbD/CbG/CbP, 6 cycles) plus bev (15 mg/kg, d1, q3w or 10 mg/kg, d1&15, q4w), stratified by platinum-free interval, PD-L1 status on biopsy at study entry and Cx cohort...Encouraging OS data warrant further analyses with longer follow-up. Further research on ATALANTE biopsy samples is warranted to better decipher the immunological landscape of PSROC.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity. (Pubmed Central) - Jul 20, 2022
Previous research has shown (hydroxy-)chloroquine is insufficient to disrupt autophagy in tumors...Only minor additive effects of autophagy drugs with Doxil were observed. Combinations of autophagy drugs may be considered for therapy in human oncology trials, with possible side effects to monitor informed by these murine pre-clinical data.
- |||||||||| ATX-101 / APIM Therap
Enrollment open, Combination therapy: A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy (clinicaltrials.gov) - Jul 19, 2022
P1b/2a, N=78, Recruiting,
Combinations of autophagy drugs may be considered for therapy in human oncology trials, with possible side effects to monitor informed by these murine pre-clinical data. Not yet recruiting --> Recruiting
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - Jul 18, 2022
P2, N=65, Recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2022 --> Jul 2023
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Preclinical, Journal: Effect of natural flavonoids to reverse P-glycoprotein-related multidrug resistance in breast cancer cell cultures. (Pubmed Central) - Jul 13, 2022
The aim of the research was to evaluate the influence of two P-glycoprotein (P-gp) inhibitors silymarin and quercetin on anticancer drug doxorubicin (DOX) and pegylated liposomal doxorubicin (PLD) delivery into breast cancer cells (2D cultures) and cancer cell spheroids (3D cultures) at different pH...However, both silymarin and quercetin enhanced DOX and PLD uptake into JC cell cultures. Silymarin and quercetin may modulate DOX and PLD transport into monolayer-cultured cells and three-dimensional cancer cell cultures depending on P-gp activity.
- |||||||||| Biomarker, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. (Pubmed Central) - Jul 6, 2022
P2
This study, the first biomarker-driven umbrella trial in platinum-resistant recurrent ovarian cancer, suggests clinical utility with biomarker-driven targeted therapy. All treatment combinations were manageable, and without unexpected toxicities.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy. (Pubmed Central) - Jul 5, 2022
The optimum formulations indicated a burst release of 30% in the presence of 0.1% hydrogen peroxide at pH 6.5, thanks to the redox-sensitive role of DDA moieties; conversely, Caelyx (PEGylated liposomal Dox) showed negligible release at this condition...The release of Dox from RS liposomes in the TME through the DDA link fracture triggered by ROS or glutathione is seemingly the prerequisite for the formulations to exert their therapeutic action. These findings suggest the potential application of such intelligent formulations in the treatment of various malignancies where the TME redox feature could be exploited to achieve an improved therapeutic response.
- |||||||||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Avastin (bevacizumab) / Roche
Trial primary completion date: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 28, 2022
P2, N=240, Recruiting,
The combination of bortezomib and PLD was well tolerated; however, antitumor activity was not sufficient to warrant further investigation in ovarian cancer. Trial primary completion date: Jul 2022 --> Jul 2023
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Tumor penetrating utorubicin-loaded polymersomes for anti-cancer therapy (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_687;
The brightest example, liposomal doxorubicin (Caelyx ®), is clinically approved for the treatment of several types of cancer...Conclusion We developed a tumor-specific nanoplatform that selectively delivers a novel drug candidate UTO to breast and peritoneal tumors and has an anti-cancer effect in a model of peritoneal carcinomatosis. Our study encourages further preclinical and clinical studies on UTO as a nanocarrier payload for precision cancer therapy with reduced drug side effects.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: BV mini CHP: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 27, 2022
P2, N=24, Active, not recruiting,
Our study encourages further preclinical and clinical studies on UTO as a nanocarrier payload for precision cancer therapy with reduced drug side effects. Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
- |||||||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Journal: Fabrication of Doxorubicin-Loaded Lipid-Based Nanocarriers by Microfluidic Rapid Mixing. (Pubmed Central) - Jun 25, 2022
The optimized LNC-Dox showed preferred release in acidic environments and better therapeutic efficacy compared to PEGylated liposomal Dox in vivo. Thus, this study provides a feasible approach to efficiently encapsulate doxorubicin into lipid-based nanocarriers fabricated by microfluidic rapid mixing.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. (Pubmed Central) - Jun 23, 2022
Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Review: Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma. (Pubmed Central) - Jun 22, 2022
Interstitial pneumonitis (IP), a potentially fatal complication of non-Hodgkin Lymphoma (NHL) patients received CHOP (cyclophosphamide and doxorubicin and vincristine and prednisone)-like chemotherapy, negatively affected patients' clinical outcome and quality of life...Among the 3 available patient-related risk factors, 6 disease-related risk factors and 3 drug-related risk factors, it was found that only drug-related risk factors were significantly associated with IP development: pegylated liposomes doxorubicin (PLD) replacement (RR = 3.25, 95% CI = 1.69-6.27, I 64%), rituximab (RTX) addition (RR = 4.24, 95% CI = 2.58-6.96, I 0) and granulocyte colony stimulating factor (G-CSF) administration (RR = 5.80, 95% CI = 3.05-11.05, I 0)...Clinicians should focus on these patients to detect and treat the IP development timely, which might bring benefit in patients' survival. PROSPERO, identifier CRD42022309884.
- |||||||||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Trial completion date, Trial primary completion date, Surgery: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov) - Jun 16, 2022
P1, N=40, Active, not recruiting,
PROSPERO, identifier CRD42022309884. Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker, Metastases: ICON: Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (clinicaltrials.gov) - Jun 15, 2022
P2b, N=82, Active, not recruiting,
Trial completion date: Dec 2027 --> Dec 2028 Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> May 2027 | Trial primary completion date: Jan 2022 --> May 2022
- |||||||||| tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 15, 2022
P1, N=80, Active, not recruiting,
Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> May 2027 | Trial primary completion date: Jan 2022 --> May 2022 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - Jun 3, 2022
P2, N=24, Active, not recruiting,
The clinical utility of the AMC as a predictor of PLD-induced HFS appears limited, at least when given with ifosfamide. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases: Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (clinicaltrials.gov) - Jun 3, 2022
P2, N=115, Recruiting,
Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Biomarker, Journal, Tumor microenvironment: Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. (Pubmed Central) - May 26, 2022
Furthermore, employing murine breast and fibrosarcoma tumor models as well as ultrasound shear wave elastography and contrast-enhanced ultrasound, we provide evidence that the approved nanomedicine Doxil can induce normalization in a dose-dependent manner by improving tumor perfusion as a result of tissue softening. Finally, we show that pretreatment with a normalizing dose of Doxil can improve the efficacy of immune checkpoint inhibition.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
Journal: Translational development of a tumor junction opening technology. (Pubmed Central) - May 21, 2022
Pretreatment with steroids and cyclophosphamide reduced anti-c-JO4 antibody response and blunted cytokine release. Our data indicate acceptable safety of our new treatment approach if immune reactions are monitored and counteracted with appropriate immune suppression.
- |||||||||| Promitil (pegylated liposomal mitomycin-c prodrug) / LipoMedix
Journal: Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy. (Pubmed Central) - May 19, 2022
Dox and MLP are available in single drug liposomal formulations: pegylated liposomal Dox (PLD, Doxil®), clinically approved, and pegylated liposomal MLP (PL-MLP, Promitil®), in phase 1-2 clinical testing...The Ald-free formulation, PLD-MLP, displayed similar pharmacokinetic properties to PLAD-MLP, but its therapeutic activity was lower. PLAD-MLP is a novel multi-drug liposome formulation with attractive pharmacological properties and powerful antitumor activity and is a promising therapeutic tool for combination cancer chemotherapy.
- |||||||||| Ovastat (treosulfan) / Medac, Medexus
Biomarker, Journal, Heterogeneity: Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. (Pubmed Central) - May 15, 2022
The second-line combination therapy of carboplatin with gemcitabine was significantly superior to the combination of carboplatin with PEGylated liposomal doxorubicin (p < 0.0001) or paclitaxel (p = 0.0007)...Treosulfan showed the highest efficacy of all nonplatinum agents, with significant advantage over vinorelbine (p < 0.0001) and topotecan (p < 0.0001), the next best agents...Biological heterogeneity observed in recurrent ovarian cancers might explain the strong differences in the clinical drug response of these patients. Preclinical drug testing and biomarker profiling in the ovarian-cancer spheroid model might help in optimizing treatment management for individual patients.
|
